SARS-CoV-2 Infection of Human Neurons Is TMPRSS2 Independent, Requires Endosomal Cell Entry, and Can Be Blocked by Inhibitors of Host Phosphoinositol-5 Kinase
- PMID: 37039676
- PMCID: PMC10134833
- DOI: 10.1128/jvi.00144-23
SARS-CoV-2 Infection of Human Neurons Is TMPRSS2 Independent, Requires Endosomal Cell Entry, and Can Be Blocked by Inhibitors of Host Phosphoinositol-5 Kinase
Abstract
2019 coronavirus disease (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition to respiratory illness, COVID-19 patients exhibit neurological symptoms lasting from weeks to months (long COVID). It is unclear whether these neurological manifestations are due to an infection of brain cells. We found that a small fraction of human induced pluripotent stem cell (iPSC)-derived neurons, but not astrocytes, were naturally susceptible to SARS-CoV-2. Based on the inhibitory effect of blocking antibodies, the infection seemed to depend on the receptor angiotensin-converting enzyme 2 (ACE2), despite very low levels of its expression in neurons. The presence of double-stranded RNA in the cytoplasm (the hallmark of viral replication), abundant synthesis of viral late genes localized throughout infected cells, and an increase in the level of viral RNA in the culture medium (viral release) within the first 48 h of infection suggested that the infection was productive. Productive entry of SARS-CoV-2 requires the fusion of the viral and cellular membranes, which results in the delivery of the viral genome into the cytoplasm of the target cell. The fusion is triggered by proteolytic cleavage of the viral surface spike protein, which can occur at the plasma membrane or from endosomes or lysosomes. We found that SARS-CoV-2 infection of human neurons was insensitive to nafamostat and camostat, which inhibit cellular serine proteases, including transmembrane serine protease 2 (TMPRSS2). Inhibition of cathepsin L also did not significantly block infection. In contrast, the neuronal infection was blocked by apilimod, an inhibitor of phosphatidyl-inositol 5 kinase (PIK5K), which regulates early to late endosome maturation. IMPORTANCE COVID-19 is a disease caused by the coronavirus SARS-CoV-2. Millions of patients display neurological symptoms, including headache, impairment of memory, seizures, and encephalopathy, as well as anatomical abnormalities, such as changes in brain morphology. SARS-CoV-2 infection of the human brain has been documented, but it is unclear whether the observed neurological symptoms are linked to direct brain infection. The mechanism of virus entry into neurons has also not been characterized. Here, we investigated SARS-CoV-2 infection by using a human iPSC-derived neural cell model and found that a small fraction of cortical-like neurons was naturally susceptible to infection. The productive infection was ACE2 dependent and TMPRSS2 independent. We also found that the virus used the late endosomal and lysosomal pathway for cell entry and that the infection could be blocked by apilimod, an inhibitor of cellular PIK5K.
Keywords: COVID-19; PIK5; SARS-CoV-2; apilimod; astrocyte; brain; central nervous system infections; iPSC; long COVID; neuron.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.mBio. 2021 Aug 31;12(4):e0097021. doi: 10.1128/mBio.00970-21. Epub 2021 Aug 3. mBio. 2021. PMID: 34340553 Free PMC article.
-
Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.J Virol. 2021 Oct 13;95(21):e0097521. doi: 10.1128/JVI.00975-21. Epub 2021 Aug 18. J Virol. 2021. PMID: 34406858 Free PMC article.
-
SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.J Virol. 2021 Apr 12;95(9):e00002-21. doi: 10.1128/JVI.00002-21. Print 2021 Apr 12. J Virol. 2021. PMID: 33608407 Free PMC article.
-
Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.J Med Virol. 2021 Sep;93(9):5260-5276. doi: 10.1002/jmv.27019. Epub 2021 May 3. J Med Virol. 2021. PMID: 33851732 Free PMC article. Review.
-
Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion.Curr Drug Targets. 2021;22(2):192-201. doi: 10.2174/1389450121666200924113243. Curr Drug Targets. 2021. PMID: 32972339 Review.
Cited by
-
Human iPSC-derived pericyte-like cells carrying APP Swedish mutation overproduce beta-amyloid and induce cerebral amyloid angiopathy-like changes.Fluids Barriers CNS. 2024 Sep 27;21(1):78. doi: 10.1186/s12987-024-00576-y. Fluids Barriers CNS. 2024. PMID: 39334385 Free PMC article.
-
SARS-CoV-2 infects neurons, astrocytes, choroid plexus epithelial cells and pericytes of the human central nervous system in vitro.J Gen Virol. 2024 Jul;105(7):002009. doi: 10.1099/jgv.0.002009. J Gen Virol. 2024. PMID: 38995681
-
Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID.NPJ Sci Food. 2024 Mar 30;8(1):19. doi: 10.1038/s41538-024-00261-2. NPJ Sci Food. 2024. PMID: 38555403 Free PMC article. Review.
-
Antiandrogens as Therapies for COVID-19: A Systematic Review.Cancers (Basel). 2024 Jan 10;16(2):298. doi: 10.3390/cancers16020298. Cancers (Basel). 2024. PMID: 38254788 Free PMC article. Review.
-
Human motor neurons derived from induced pluripotent stem cells are susceptible to SARS-CoV-2 infection.Front Cell Neurosci. 2023 Dec 5;17:1285836. doi: 10.3389/fncel.2023.1285836. eCollection 2023. Front Cell Neurosci. 2023. PMID: 38116398 Free PMC article.
References
-
- Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, Lange F, Andersson JLR, Griffanti L, Duff E, Jbabdi S, Taschler B, Keating P, Winkler AM, Collins R, Matthews PM, Allen N, Miller KL, Nichols TE, Smith SM. 2022. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 604:697–707. doi:10.1038/s41586-022-04569-5. - DOI - PMC - PubMed
-
- Matschke J, Lütgehetmann M, Hagel C, Sperhake JP, Schröder AS, Edler C, Mushumba H, Fitzek A, Allweiss L, Dandri M, Dottermusch M, Heinemann A, Pfefferle S, Schwabenland M, Sumner MD, Bonn S, Prinz M, Gerloff C, Püschel K, Krasemann S, Aepfelbacher M, Glatzel M. 2020. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol 19:919–929. doi:10.1016/S1474-4422(20)30308-2. - DOI - PMC - PubMed
-
- Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, Laue M, Schneider J, Brünink S, Greuel S, Lehmann M, Hassan O, Aschman T, Schumann E, Chua RL, Conrad C, Eils R, Stenzel W, Windgassen M, Rößler L, Goebel HH, Gelderblom HR, Martin H, Nitsche A, Schulz-Schaeffer WJ, Hakroush S, Winkler MS, Tampe B, Scheibe F, Körtvélyessy P, Reinhold D, Siegmund B, Kühl AA, Elezkurtaj S, Horst D, Oesterhelweg L, Tsokos M, Ingold-Heppner B, Stadelmann C, Drosten C, Corman VM, Radbruch H, Heppner FL. 2021. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci 24:168–175. doi:10.1038/s41593-020-00758-5. - DOI - PubMed
-
- Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S, Braun F, Lu S, Pfefferle S, Schröder AS, Edler C, Gross O, Glatzel M, Wichmann D, Wiech T, Kluge S, Pueschel K, Aepfelbacher M, Huber TB. 2020. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med 383:590–592. doi:10.1056/NEJMc2011400. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous